Janssen-cilag Ltd.

This study tracks 220 adults with moderate-to-severe ulcerative colitis or Crohn's disease who are starting guselkumab, a biologic drug. Researchers will measure how many achieve remission (symptom control) and whether they can stop steroids. The goal is to see how well the drug …

This study follows 200 adults with psoriatic arthritis who are starting guselkumab as part of their normal care. Researchers will track how many patients continue the treatment after one and two years, and why some stop. The goal is to understand how well the drug works in real-w…

This study watches 200 adults with moderate to severe psoriasis who switch from ustekinumab to guselkumab in everyday medical practice. Researchers track how well the new drug clears skin symptoms and check for side effects over 52 weeks. The goal is to see if guselkumab works sa…

This study collects information from about 900 people with relapsed/refractory multiple myeloma who received teclistamab or talquetamab in regular medical practice, not in a clinical trial. Researchers will look at how well the drugs work, how long benefits last, and what side ef…